# Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

> **NCT03984812** · PHASE1 · TERMINATED · sponsor: **ViiV Healthcare** · enrollment: 24 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK3732394
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03984812
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-17
- **Primary completion:** 2020-03-23
- **Final completion:** 2020-03-23
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The study was terminated early (following completion of SAD Cohort 3; 80 mg) based on PK/PD modelling which demonstrated the medicine's intended target profile was not achievable.
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03984812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03984812, "Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03984812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*